FDA warns Amneal over visible particles in ropivacaine injection and inadequate investigations and endotoxin lab controls.
What happened
FDA inspected Amneal Pharmaceuticals Private Limited in Gujarat, India, from March 10 to 19, 2025. FDA found inadequate investigations into visible particulate matter in ropivacaine hydrochloride injection bags, including relaxed defect limits and a risk assessment that minimized patient risk. FDA also found bacterial endotoxin test deficiencies, including improper pipetting, rapid gel-clot reading, and non-contemporaneous documentation.
What FDA found
The company did not thoroughly investigate visible particle contamination in ropivacaine injection and continued using polypropylene bags linked to the particles.
21 CFR 211.192The company's risk assessment minimized the danger of particles in an epidural injectable and did not adequately consider route of administration or patient population.
21 CFR 211.192The company relaxed defect and rejection limits for polypropylene bags, allowing poor-quality bags to be used in sterile injectable production.
21 CFR 211.192The company's bacterial endotoxin testing had deficiencies, including incomplete pipette discharge, rapid gel-clot reading, inadequate verification, and non-contemporaneous documentation.
21 CFR 211.160(b)The quality unit was not fully exercising its authority and/or responsibilities and lacked sufficient resources.
What FDA wants
FDA asks Amneal to correct the violations promptly and respond in writing within 15 working days with assessments, CAPA plans, and other requested information; if corrective actions cannot be completed in that time, the company must state why and give a schedule. FDA also asks the company to contact CDER's Drug Shortages Staff if an action may disrupt supply.
Who should pay attention
- hospitals and clinics that use epidural injectables
- companies buying sterile injectables from contract manufacturers
- makers and qualifiers of polypropylene bags for parenteral drugs
This is a summary. Read the original letter on fda.gov.